Introducing a Shareholder Special Benefit conduct company(NISSUI PHARMACEUTICAL)

Today I will talk about NISSUI PHARMACEUTICAL, a medicine manufacturing company involved in producing clinical diagnostic medicine, industrial inspection medicine, and general medicine.

The above images are from Nissui Pharmaceutical’s website.

 

4550 NISSUI PHARMACEUTICAL

Since I am not familiar with the medical and pharmaceutical fields, I will not mention in detail, NISSUI PHARMACEUTICAL has the top market share in the field of bacteriological examination, and it seems to develop products in the field of regenerative medicine.
In addition, its business domain extends beyond my own initial products, such as providing nutrient media that uses mammal organs as raw materials or providing a simple medium culture for bacteria count measurement to food manufacturing companies.

 

1,198 5/24 last closing price) The latest stock price← click here  Trading unit: 100  

The final month of the settlement: March  Dividend yield 3.34%   PER 26.46  PBR 0.82

Equity ratio 55.5%

 

Pharmaceutical stocks are characterized by their performance which does not necessarily coincide with the wave of economic fluctuations, and sometimes their performance may greatly increase if one drug bursts onto the scene.

Since I am complete novice in medicine matters, there in no way I can predict the outcome, so I will keep holding it with patience, and resign to my fate.

In addition to dividends, NISSUI PHARMACEUTICAL has set up a shareholder special benefit and twice a year you can receive a 500 yen Quo card.

 

NISSUI PHARMACEUTICAL special benefits ← For details click here

Transition of business results

 

Net sales

Operating

profit

Net profit

Net profit

per share

dividend

Dividend

payout ratio

2017.3

12,825

1,697

1,902

85.0

40

47%

2018.3

12,329

1,427

1,175

52.5

40

76%

2019.3

12,549

1,312

784

35.0

40

114%

2020.3

13,300

1,330

1,014

45.3

40

88%

Unit of sales, operating profit, net income is one-million yen

The figure for March, 2020 is the predicted value

 

Cash flow statement

2019.3

2018.3

CF operating activities

1,364

865

CF investing activities

10,527

362

CF financing activities

930

929

One unit is one hundred million yen

Note: You should be responsible for your own investment. Please make your own final judgment.